Aeterna Zentaris Commences Promotional Activities for APIFINY® Prostate Cancer Blood Test

CHARLESTON, S.C. -- Aeterna Zentaris Inc. (NASDAQ: AEZS, TSX: AEZ) (the “Company”) today announced that it has started promoting APIFINY®, the only cancer specific, non-PSA blood test for the evaluation of the risk of prostate cancer, in 20 U.S. territories pursuant to its co-marketing agreement with Armune BioScience, Inc.


Innovative Public Relations - Relentless Innovation. Proven Results.
Sharing Your Brand, Your Message

Under the co-marketing agreement, the Company will promote APIFINY to designated medical professionals and will receive a commission for each test performed resulting from its targeted promotion. Jude Dinges, Senior Vice President and Chief Commercial Officer of Aeterna Zentaris, commented: “Our sales force has initiated the promotion of APIFINY, the only cancer specific, non-PSA based blood test available today. Given its ability to measure the immune-system response to prostate cancer, we believe APIFINY represents an important addition to clinical information for patients and their clinicians pertaining to the risk assessment for prostate cancer.”

About Prostate Cancer

Other than skin cancer, prostate cancer is the most common cancer in American men. The American Cancer Society predicted that 220,800 new cases of prostate cancer in the United States would occur in 2015, that there would be 27,540 prostate cancer deaths during the year and that one man in seven would be diagnosed with prostate cancer during his lifetime. Approximately 60% of prostate cancer is diagnosed in men aged 65 or older, and it is rare before age 40. Prostate cancer is the second leading cause of cancer death in American men, behind only lung cancer. Prostate cancer can be a serious disease, but most men diagnosed with prostate cancer do not die from it. In fact, more than 2.9 million men in the United States who have been diagnosed with prostate cancer at some point are still alive today.

About APIFINY®

APIFINY is the only cancer-specific, non-PSA blood test that is designed to aid clinicians in the risk assessment for prostate cancer. APIFINY technology measures the body’s immune response to cancer and is based on the measurement of eight prostate-cancer-specific autoantibodies in human serum. These autoantibodies are produced and amplified by the immune system in response to the presence of prostate cancer cells. The autoantibodies are stable and, because of their amplification, are likely to be abundant and easy to detect, especially with small tumors characteristic of early-stage cancers. The autoantibody markers span a range of biological functions integral to prostate-cancer progression. Cell cycle, structure, and cellular signaling pathways are all represented. The use of APIFINY results supplement other information about a patient’s risk of prostate cancer and may therefore aid clinicians in the detection of prostate cancer.

About Armune BioScience

Armune is a medical diagnostics company that develops and commercializes unique proprietary technology exclusively licensed from the University of Michigan for diagnostic and prognostic tests for cancer. The Armune BioScience Laboratory is a commercial reference laboratory, certified and regulated by the federal Clinical Laboratory Improvement Amendments (CLIA) law established in 1988. The laboratory’s CLIA Certificate permits it to perform APIFINY and other high-complexity medical tests. Armune, a private company, has a corporate headquarters in Kalamazoo, MI and a research and commercial laboratory in Ann Arbor, MI. For more information, visit www.armune.com.

About Aeterna Zentaris

Aeterna Zentaris is a specialty biopharmaceutical company engaged in developing and commercializing novel treatments in oncology, endocrinology and women’s health. We are engaged in drug development activities and in the promotion of products for others. We are now conducting Phase 3 studies of two internally developed compounds. The focus of our business development efforts is the acquisition of or licenses to products that are relevant to our therapeutic areas of focus. We also intend to license out certain commercial rights of internally developed products to licensees in territories where such out-licensing would enable us to ensure development, registration and launch of our product candidates. Our goal is to become a growth-oriented specialty biopharmaceutical company by pursuing successful development and commercialization of our product portfolio, achieving successful commercial presence and growth, while consistently delivering value to our shareholders, employees and the medical providers and patients who will benefit from our products. For more information, visit www.aezsinc.com.